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Abstract  297 / 300 words 
Introduction: Cancer-associated adipocytes metabolically interact with adjacent cancer 
cells to promote tumor proliferation and metastasis. Fatty acid binding protein 4 (FABP4) 
participates in this interaction, and is gathering attention as a therapeutic and diagnostic 
target. Positron emission tomography (PET) is a useful diagnostic method that enables 
noninvasive in vivo quantitative imaging of biofunctional molecules with probes labeled 
with positron-emitting radioisotopes. Here a novel 18F labeled probe for PET FABP4 
imaging developed through dedicated drug design from a radioiodinated probe we 
recently reported is evaluated in vitro and in vivo.  
Methods: We designed the [18F]-labeled FTAP1 and FTAP3 probe, composed of a single 
or triple oxyethylene linker and a triazolopyrimidine scaffold derived from a FABP4 
inhibitor. FABP4 binding affinities for chemically synthesized FTAP1 and FTAP3 were 
measured using FABP4 and 8-anilino-1-naphthalene sulfonic acid. Cell membrane 
permeability was measured using a commercially available plate assay system. After 
radiosynthesis, [18F]FTAP1 affinity and selectivity were evaluated using immobilized 
FABP3, FABP4, and FABP5. Cell uptake was investigated using differentiated adipocytes 
expressing FABP4 with inhibitor treatment. Following biodistribution studies in C6 
glioblastoma-bearing mice, ex vivo autoradiography and immunohistochemistry were 
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performed using thin sliced tumor sections. PET/CT imaging was then performed on C6 
tumor bearing mice. 
Results: FTAP1 showed high FABP4 affinity (Ki= 68 ± 8.9 nM) and adequate cell 
permeability. [18F]FTAP1 with ≥ 98% radiochemical purity was shown to selectively bind 
to FABP4 (16.3- and 9.3-fold higher than for FABP3 and FABP5, respectively). 
[18F]FTAP1 was taken up by FABP4 expressing cells, and this uptake could be blocked 
by an inhibitor, indicating very low non-specific cell binding. [18F]FTAP1 showed high 
tumor accumulation, which demonstrates its potential use for in vivo tumor PET imaging, 
and the intratumoral radioactivity distribution corresponded to the FABP4 expression 
profile.  






According to a 2011 report [1], more than 500 million adults worldwide were 
recognized as obese. Obesity is a major concern because it represents an important risk 
factor for diabetes, hypertension and cardiovascular diseases. The impact of obesity on 
cancer survival has been also noted. Renehan et al. reported that an increase in body mass 
index is a risk factor for some cancers, including esophageal adenocarcinoma and thyroid 
cancers [2]. The systemic pharmacological effect of adipokines secreted by adipocytes as 
well as increased insulin levels are major mechanisms of obesity in cancer development. 
In addition, cancer-associated adipocytes (CAAs) play an important role in tumor 
progression [3, 4], as was indicated by in vitro and in vivo evidence showing that CAAs 
promote tumor cell survival, proliferation, differentiation and migration [4, 5]. Although 
the detailed mechanisms are not fully elucidated, the interaction of CAAs with tumor cells 
seems to depend on biologically active substances such as interleukin 6 (IL-6) and free 
fatty acids [4]. 
Fatty acid binding proteins (FABPs) regulate lipid responses in cells and are involved 
in metabolic and inflammatory pathways [6]. Through the transportation of lipids to 
specific cell components, FABPs regulate lipid usage in cells for storage, signaling and 
transcriptional regulation. Among the FABPs, FABP4 is the best-characterized isoform 
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and is predominantly expressed in adipocytes and macrophages [6]. FABP4 regulates the 
activities of Jun N-terminal kinase (JNK) 1 to enhance production of cytokines such as 
tumor necrosis factor α (TNF-α), IL-1β, and monocyte chemoattractant protein 1 (MCP-
1) [7, 8]. CAAs were recently reported to interact metabolically with cancer cells through 
the transport of free fatty acids on the cellular boundary, and this interaction could be 
inhibited by treatment of cells with a FABP4 selective inhibitor [5]. Furthermore, tumor 
proliferation and metastasis were significantly diminished in FABP4-knockout mice [5], 
indicating an important role for FABP4 in the metabolic interaction between CAAs and 
cancer cells as well as in tumor progression. Therefore, given the promise of FABP4 as a 
therapeutic target in such tumors, in vivo noninvasive imaging techniques are urgently 
needed for the development of therapeutic agents that target FABP4 and also to evaluate 
the functions of FABP4 in tumors. 
We recently developed a FABP4 imaging probe, [123/125I]TAP1, for use in nuclear 
imaging with single photon emission computed tomography (SPECT) [9]. Although the 
design of [123/125I]TAP1 was based on the structures of selective FABP4 inhibitors and 
showed high affinity and selectivity for FABP4, this probe had high lipophilicity that 
caused significant nonspecific distribution in vivo. This lipophilicity was considered to 
be a limitation of this probe that required improvement before it could be used in 
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expanded in vivo imaging applications. Thus, we aimed to develop a FABP4 imaging 
probe that could be applied to in vivo FABP4 imaging in model mice using nuclear 
medical techniques. We describe the design of two candidate probes, [18F]FTAP1 and 
[18F]FTAP3 (Fig. 1), which are based on [123I]TAP1. To reduce and optimize probe 
lipophilicity that will promote adequate intracellular targeting, we introduced 
radiofluorine (18F) as the radioisotope for labeling for positron emission tomographic 
(PET) imaging at the same labeling position as in [123/125I]TAP1 and introduced 
oxyethylene linkers with two different chain lengths for subtle lipophilicity control. We 
then synthesized and evaluated the usefulness of [18F]FTAP1 and [18F]FTAP3 in vitro and 
in vivo, and found that [18F]FTAP1 is a promising FABP4 imaging probe. 
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Materials and Methods 
1. General 
All reagents were purchased from Nacalai Tesque, Inc. and Wakenyaku Co., Ltd., 
and were used without further purification unless otherwise noted. 1H-NMR spectra were 
obtained at 400 MHz on JEOL JNM-AL400 NMR spectrometers at room temperature 
with tetramethylsilane (TMS) as an internal standard. Chemical shifts are reported as δ 
values (parts per million) relative to the TMS standard. Coupling constants are reported 
in Hertz. Multiplicity is defined by s (singlet), d (doublet), t (triplet), and m (multiplet). 
High resolution mass spectra (HRMS) were acquired on a JMS-SX 102A QQ or JMS-
GC-mate mass spectrometer (JEOL). Recombinant hexahistidine (his)-tagged FABP3, 
FABP4 and FABP5 proteins were purchased from Cayman Chemical Company (Ann 
Arbor, MI, USA). All PET scans were obtained on a small-animal scanner (FX3300 
imager; SII NanoTechnology Inc., Northridge, CA, USA). 
 
2. Animals & Cells 
Animal experiments were conducted in accordance with our institutional guidelines 
and approved by the Kyoto University Animal Care Committee (Permit Number: 2012-
49, 2013-33). Male ddY mice and male Balb/c nu-nu mice (Japan SLC, Inc.) were fed 
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standard chow and had access to water ad libitum. All surgery was performed under 
isoflurane anesthesia, and all efforts were made to minimize suffering. Rat C6 glioma 
cells (Health Science Research Resources Bank) were cultured at 37 °C in 5% CO2 in 
McCoy's 5A Modified Medium supplemented with 10% heat-inactivated fetal bovine 
serum (FBS, Nichirei Bioscience Inc.), 50 U/ml penicillin and 50 μg/ml streptomycin 
(Nacalai Tesque, Inc.). C6 cells were suspended in PBS(-) followed by subcutaneous 
inoculation into the right hind legs of Balb/c nu-nu mice (5 x 106 cells/100 μl). The 
animals were used for experiments 14 days after inoculation. 
Murine 3T3-L1 preadipocytes (American Type Culture Collection) were cultured in 
Dulbecco's Modified Eagle Medium (DMEM, Nissui Pharmaceutical Co., Ltd.) 
supplemented with 10% heat-inactivated FBS, 50 U/ml penicillin and 50 μg/ml 
streptomycin at 37 °C in 5% CO2. Differentiation of 3T3-L1 cells was performed as 
described previously [10]. Briefly, 2 days after confluence was reached, the medium was 
replaced with DMEM containing 10% FBS and inducers (0.25 mM dexamethasone, 10 
μg/ml insulin, 0.5 mM 3-isobutyl-1-methylxanthine and 10 μM pioglitazone 
hydrochloride) for 2 days. The medium was then changed to DMEM supplemented with 
10% FBS, 10 μg/ml insulin and 10 μM pioglitazone hydrochloride, and then incubated 
for 2 days. The medium was then changed every other day with DMEM supplemented 
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with 10% FBS and 10 μM pioglitazone hydrochloride. After 8-10 days, the differentiated 
adipocytes were confirmed by western blotting and Oil red O staining following our 
previous studies [9, 10] and used for experiments. 
 
3. Chemistry 
Nonradioactive FTAP1, nonradioactive FTAP3, and FTAP1 precursors were 
synthesized as shown in Fig. 1. In each step in general, the solvent was evaporated under 
reduced pressure after the reaction, water was added, and the product was extracted into 
ethyl acetate. After the organic layer was dried over Na2SO4 and filtered, the solvent was 
evaporated and the residue was purified by silica gel chromatography.  
 
5-(Chloromethyl)-2-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one (1) 
Compound 1 was synthesized according to previously reported procedures [11].  
 
1-(Benzyloxy)-3-(2-fluoroethoxy)benzene (2) 
3-Benzyloxyphenol (0.9 g, 4.6 mmol) and 2-fluoroethyl 4-methylbenzenesulfonate 
(1.0 g, 4.6 mmol) were reacted overnight at 105 °C in the presence of K2CO3 (1.3 g, 9.2 
mmol) in DMF (27 ml). Silica gel chromatography (ethyl acetate/hexane = 1/8) to yield 
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2 (0.9 g, 3.7 mmol, 80 % yield). 1H NMR: (CDCl3, 400 MHz) 7.44-7.31 (m, 5H), 7.21-
7.17 (t, 1H, J=8.5 Hz), 6.63-6.53 (m, 3H), 5.05 (s, 2H), 4.81-4.67 (td, 2H, J=4.4, 47 Hz), 




A mixture of 2 (0.9 g, 3.7 mmol) and palladium carbon (Pd 10%, 0.1 g) was stirred 
in methanol (30 ml) at room temperature for 1 hr under a hydrogen atmosphere at 
atmospheric pressure. After filtration, the solvent was evaporated. The residue (0.7 g, 4.3 
mmol) and 1 (0.8 g, 2.9 mmol) were then reacted in the presence of K2CO3 (1.2 g, 8.7 
mmol) in DMF (45 ml) at 85 °C overnight. Silica gel chromatography (CHCl3/methanol 
= 20/1) to yield 3 (nonradioactive FTAP1, 0.1 g, 0.3 mmol, 11 % yield). 1H NMR: 
(DMSO-d6, 400 MHz) 8.13-8.11 (d, 2H, J=8.2 Hz), 7.55-7.53 (m, 3H), 7.27-7.22 (t, 1H, 
J=8.0 Hz), 6.69-6.62 (m, 3H), 6.12 (s, 1H), 5.11 (s, 2H), 4.81-4.19 (m, 4H). HRMS 
(FAB+): the calculated m/z for C20H18FN4O3 was 381.1363, and the actual m/z was 
381.1360. 
 
2-{2-(2-Fluoroethoxy)ethoxy}ethyl 4-methylbenzenesulfonate (4) 
11 
 
Tetrabutylammonium fluoride (6.3 g, 24 mmol) was added to 1,2-bis[2-(p-
toluenesulfonyloxy)ethoxy]ethane (1.0 g, 20 mmol) in THF (40 ml) at room temperature. 
The mixture was stirred at 85 °C for 8 hr. Silica gel chromatography (ethyl acetate/hexane 
= 1/2) to yield 4 (1.1 g, 3.6 mmol, 18 % yield). 1H NMR: (CDCl3, 400 MHz) 7.81-7.79 
(d, 2H, J=7.8 Hz), 7.36-7.33 (d, 2H, J=8.7 Hz), 4.61-4.59 (t, 1H, J=4.1 Hz), 4.49-4.47 (t, 
1H, J=4.1 Hz), 4.18-4.16 (t, 2H, J=4.8 Hz), 3.76-3.74 (t, 1H, J=4.1 Hz), 3.71-3.59 (m, 
7H), 2.45 (s, 3H). 
 
1-(Benzyloxy)-3-[2-{2-(2-fluoroethoxy)ethoxy}ethoxy]benzene (5) 
3-Benzyloxyphenol (0.1 g, 0.7 mmol) and 4 (0.2 g, 0.7 mmol) were reacted in the 
presence of K2CO3 (0.2 g, 1.4 mmol) in DMF (5 ml) at 105 °C overnight. Silica gel 
chromatography (ethyl acetate/hexane = 1/3) to yield 5 (0.2 g, 0.5 mmol, 72 % yield). 1H 
NMR: (CDCl3, 400 MHz) 7.44-7.32 (m, 5H), 7.19-7.15 (t, 1H, J=8.0 Hz), 6.59-6.51 (m, 
3H), 5.04 (s, 2H), 4.63-4.49 (m, 2H), 4.12-4.10 (t, 2H, J=4.3 Hz), 3.89-3.84 (t, 2H, J=5.0 






A mixture of 5 (0.1 g, 0.70 mmol) and palladium carbon (Pd 10%, 0.01 g) was stirred 
in methanol (5 ml) at room temperature for 2 hr under a hydrogen atmosphere. After 
filtration, the solvent was evaporated. Then, the residue (0.04 g, 0.2 mmol) and 1 (0.03 g, 
0.1 mmol) were reacted in the presence of K2CO3 (0.02 g, 0.16 mmol) in DMF (5 ml) at 
85 °C for 5 hr. Silica gel chromatography (CHCl3/methanol = 10/1) to yield 6 
(nonradioactive FTAP3, 0.005 g, 0.01 mmol, 13 % yield). 1H NMR: (DMSO-d6, 400 
MHz) 8.14-8.12 (d, 2H, J=7.3 Hz), 7.55-7.53 (m, 3H), 7.25-7.21 (t, 1H, J=8.0 Hz), 6.66-
6.59 (m, 3H), 6.11 (s, 1H), 5.10 (s, 2H), 4.57-4.44 (m, 2H), 4.10-4.08 (t, 2H, J=4.4 Hz), 
3.75-3.58 (m, 8H). HRMS (FAB+): the calculated m/z for C24H26FN4O5 was 469.1887, 
and the actual m/z was 469.1889. 
  
2-{3-(Benzyloxy)phenoxy}ethanol (7) 
3-Benzyloxyphenol (2.0 g, 10 mmol) and ethylene bromohydrin (3.8 g, 30 mmol) 
were reacted overnight in the presence of K2CO3 (4.1 g, 30 mmol) in DMF (70 ml) at 
85 °C. Silica gel chromatography (ethyl acetate/hexane = 1/3) to yield 7 (1.7 g, 7.0 mmol, 
70 % yield). 1H NMR: (CDCl3, 400 MHz) 7.44-7.33 (m, 5H), 7.21-7.17 (t, 1H, J=8.5 Hz), 





Tert-butyldimethylsilyl chloride (1.7 g, 11.2 mmol) and imidazole (1.0 g, 15 mmol) 
were added to 7 (1.7 g, 7.0 mmol) in CH2Cl2 (20 ml) at 4 °C. The mixture was stirred at 
room temperature for 5 hr. Silica gel chromatography (ethyl acetate/hexane = 1/15) was 
performed. Then, the recovered sample (2.3 g, 6.5 mmol) and palladium carbon (Pd 10%, 
0.2 g) was stirred in methanol (50 ml) at room temperature for 3 hr under a hydrogen 
atmosphere. After filtration, the solvent was evaporated and purified by silica gel 
chromatography (ethyl acetate/hexane = 1/8) to yield 8 (1.7 g, 6.3 mmol, 88 % yield). 1H 
NMR: (CDCl3, 400 MHz) 7.13-7.09 (t, 1H, J=8.5 Hz), 6.50-6.41 (m, 3H), 4.02-3.94 (m, 




1 (0.6 g, 2.5 mmol) and 8 (1.0 g, 3.7 mmol) were reacted for 6 hr in the presence of 
K2CO3 (1.0 g, 7.5 mmol) in DMF (50 ml) at 85 °C. Silica gel chromatography 
(CHCl3/methanol = 30/1) was performed. Tetrabutylammonium fluoride (0.3 g, 1.0 
mmol) was added to the recovered sample (0.4 g, 0.8 mmol) in THF (15 ml) at 4 °C. The 
mixture was stirred at room temperature for 2 hr. Silica gel chromatography 
14 
 
(CHCl3/methanol = 10/1) to yield 9 (0.2 g, 0.5 mmol, 19 % yield). 1H NMR: (DMSO-d6, 
400 MHz) 8.13-8.11 (dd, 2H, J=8.2, 1.4 Hz), 7.54-7.48 (m, 3H), 7.22-7.18 (t, 1H, J=8.7 




yl)methoxy}phenoxy]ethyl 4-methylbenzenesulfonate (10) 
p-Toluenesulfonyl chloride (0.1 g, 0.7 mmol), triethylamine (0.1 g, 1.0 mmol) and 
N,N-dimethyl-4-aminopyridine (0.006 g, 0.05 mmol) were added to 9 (0.2 g, 0.5 mmol) 
in CH2Cl2 (10 ml) at 4 °C. The mixture was stirred at room temperature for 6 hr. Silica 
gel chromatography (CHCl3/methanol = 30/1) to yield 10 (FTAP1 precursor, 0.02 g, 0.04 
mmol, 7.9 % yield). 1H NMR: (DMSO-d6, 400 MHz) 8.14-8.11 (d, 2H, J=10.1 Hz), 7.81-
7.79 (d, 2H, J=8.2 Hz), 7.55-7.47 (m, 5H), 7.23-7.19 (t, 1H, J=7.8 Hz), 6.67-6.49 (m, 3H), 
6.11 (s, 1H), 5.09 (s, 2H), 4.34-4.32 (m, 2H), 4.17-4.15 (m, 2H), 2.41 (s, 3H). 
 
4. In vitro evaluation of nonradioactive compounds 
The binding affinity of FTAP1 and FTAP3 for FABP4 was measured by competitive 
binding experiments using 8-anilino-1-naphthalene sulfonic acid (1,8-ANS) as the tracer 
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[12]. Briefly, a mixture containing 0.12 ml phosphate buffer (50 mM, pH = 7.4), 0.03 ml 
FTAP1 or FTAP3 (65 μM-4 nM) in DMSO, 0.075 ml 1,8-ANS (24 nM) in phosphate 
buffer (0.2% ethanol, v/v) and 0.075 ml FABP4 (1 μM) in phosphate buffer was incubated 
at room temperature for 5 min. The fluorescence intensity at an excitation and emission 
wavelength of 370 and 475 nm, respectively, was plotted, and values for the half-maximal 
inhibitory concentration (IC50) were determined from displacement curves of three 
independent experiments using GraphPad Prism 5 (GraphPad Software, San Diego, CA). 
The inhibition constants (Ki) were calculated using the Cheng-Prusoff equation: Ki = 
IC50/(1+[L]/Kd), where [L] is the 1,8-ANS concentration and Kd is the 1,8-ANS 
dissociation constant. The Kd value of 1,8-ANS for FABP4 was previously calculated to 
be 1.2 μM [9]. 
The membrane permeability of FTAP1 and FTAP3 was measured using a pre-coated 
parallel artificial membrane permeation assay (PAMPA) plate system (BD Biosciences) 
following the manufacturer’s procedures. Briefly, the test compounds (100-200 μM, 0.2 
ml) were added to the donor plate and PBS (-) (0.2 ml) was added to the acceptor plate in 
the PAMPA plate assembly. After coupling both plates together and incubating at room 
temperature for 5 hr, 0.15 ml of the sample was obtained from each plate and 0.15 ml of 
the original compound solution was also obtained. Then, the absorbance of each sample 
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was measured at 280 nm. The permeability was calculated as: Pe (cm/s) = (-ln[1-
CA/Cequilibrium])/St (1/VD+1/VA) and Cequilibrium = [CDVD+CAVA]/(VD+VA). CD = C0 (AD-
Abuffer)/(A0-Abuffer) and CA = C0 (AA-Abuffer)/(A0-Abuffer). C0 is the concentration of the 
starting sample and A0, Abuffer, AD and AA are absorbances of the starting sample, buffer, 
donor and acceptor, respectively. VD and VA are the donor and acceptor volumes, 
respectively. S is the membrane area and t is the incubation time. 
 
5. Radiosynthesis of [18F]FTAP1 
[18F]Fluoride was produced in a cyclotron, trapped on an anion exchange cartridge, 
and eluted with a K2CO3 solution (33 mM). Kryptofix222 (20 mg) was dissolved in a 
solution of [18F]fluoride in water. The solvent was then removed at 120 °C under a stream 
of nitrogen gas. The residue was azeotropically dried with 0.3 ml of anhydrous CH3CN 
twice at 120 °C under a stream of nitrogen gas. A solution of the mesylate precursor 10 
(2.0 mg) in DMSO (0.2 ml) was added to the reaction vessel and heated at 130 °C for 2 
min under microwave (50W, SAIDA PMCR-50). After cooling to room temperature, the 
mixture was passed through a preconditioned Sep-Pak Plus C18 cartridge (Waters). The 
cartridge was washed with 20 ml water, and eluted with 3 ml CH3CN. After the solvent 
was removed, the residue was dissolved in CH3CN and subjected to RP-HPLC for 
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purification (Nacalai Tesque, 5C18-AR-ІІ, 10 mm x 250 mm, CH3CN/water = 50/50 (0 
min)-70/30 (40 min); flow rate = 1.5 ml/min). Radiochemical purity of purified 
[18F]FTAP1 was evaluated with another RP-HPLC analysis. The decay-uncorrected 
radiochemical yield of [18F]FTAP1 from [18F]KF was determined with a dose calibrator. 
 
6. In vitro evaluation of [18F]FTAP1 
For protein immobilization, his-tagged FABP3 (0.75 mg/ml, 0.003 ml, 1.5 μg), 
FABP4 (0.75 mg/ml, 0.002 ml, 1.5 μg) and FABP5 (0.70 mg/ml, 0.002 ml, 1.4 μg) in 50 
mM phosphate buffer containing 100 mM NaCl (20% glycerol, v/v, pH = 7.2) were 
incubated with 0.02 ml Ni-NTA Magnetic Agarose Beads (Qiagen) and 0.5 ml protein 
binding buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH = 8.0) at room 
temperature for 1 hr following the manufacturer’s procedures. After supernatant removal, 
protein binding buffer with 1% BSA was added, and incubated at room temperature for 
30 min. After removal of the supernatant, 0.4 ml of interaction buffer (50 mM NaH2PO4, 
300 mM NaCl, 10 mM imidazole, and 0.005% Tween, v/v, pH = 8.0) and 0.05 ml of 
interaction buffer including [18F]FTAP1 (0.08 MBq, 5% ethanol, v/v) were added. For 
measurement of non-specific binding, 0.05 ml of nonradioactive FTAP1 in interaction 
buffer (5% ethanol, v/v, 1.1 μM) was added to [18F]FTAP1. After incubation at room 
18 
 
temperature for 2 hr, the supernatants were removed, and the beads washed with 
interaction buffer (5% ethanol, v/v). The radioactivity of beads in the tubes was measured 
with a well-type γ-counter (1480 Wizard3, PerkinElmer Japan Co., Osaka, Japan). 
Binding ratios were calculated as (radioactivity of beads)/(total applied 
radioactivity)/(protein abundance on beads) x 100 (% dose/μg protein). 
For cell uptake studies, medium from 24-well plates in which differentiated 
adipocytes or undifferentiated 3T3-L1 cells were cultured was removed. After washing 
with PBS(-), 0.5 ml BMS309403 in DMEM (0-10 μM, 1% DMSO, v/v) was added and 
incubated at 37 °C for 1 hr. Then, 0.05 ml [18F]FTAP1 (0.22 MBq, 1% DMSO and 0.1 % 
Tween 20, v/v) was added and incubated at 37 °C for 1 hr. After washing with 0.5 ml 
PBS(-) (1% DMSO and 0.1 % Tween 20, v/v) three times, the cells were lysed with 0.25 
ml 2N NaOH for radioactivity and protein content measurements. Binding ratios were 
calculated as: (radioactivity in collected cells)/(total applied radioactivity)/(protein 
abundance) x 100 (% dose/mg protein).  
The [18F]FTAP1 partition coefficient was measured with 1-octanol and phosphate 
buffer at pH 7.4. The two phases were pre-saturated, and a mixture of 3.0 ml 1-octanol 
and 3.0 ml PBS(-) was added to a tube containing 0.02 ml [18F]FTAP1 in PBS(-) (0.16 
MBq, 5% DMSO, v/v). The test tube was vortexed and centrifuged (1,000 x g, 5 min). 
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Aliquots from the 1-octanol and buffer phases (0.5 ml) were counted with a well-type γ-
counter. This procedure was repeated three times. The partition coefficient was calculated 
from the ratio of radioactivity in the organic and aqueous layers. 
The in vitro stability of [18F]FTAP1 in plasma was measured using plasma samples 
taken from ddY mice (males, 7 weeks old). After addition of 0.01 ml [18F]FTAP1 (0.08 
MBq, 5% DMSO, v/v) to 0.1 ml plasma, the mixture was incubated at 37 °C for 2 hr. 
After addition of 0.2 ml methanol and vortexing, the mixture was centrifuged (4,160 x g, 
10 min). The supernatant was filtered with a low protein binding hydrophilic PTFE 
membrane (Millex-LH MILLIPORE), and the filtrate was analyzed by RP-HPLC using 
a Cosmosil C18 column (5C18-AR-ІІ, 10 mm x 250 mm, CH3CN/water = 50/50 (0 min)-
70/30 (40 min); flow rate = 1.5 ml/min). 
The serum protein binding ratio of [18F]FTAP1 was measured using rapid equilibrium 
dialysis (RED) devices (Thermo Fisher Scientific K.K.) following the manufacturer’s 
procedures. Briefly, 0.02 ml [18F]FTAP1 (0.43 MBq, 5% ethanol, v/v) and mouse plasma 
(0.3 ml) were mixed and placed in the sample chamber with 0.5 ml PBS (-) added to the 
RED device buffer chamber. After incubation at 37 °C for 4 hr, 0.05 ml of the samples 
were obtained from each chamber. The binding ratios were calculated as: (sample 





7. In vivo and ex vivo evaluations of [18F]FTAP1 
A saline solution of [18F]FTAP1 (0.07-0.10 MBq, 0.1% Tween 20, v/v) was injected 
intravenously into a lateral tail vein of C6 cell implantation model mice (males, 8 weeks 
old). The mice were sacrificed at various post-injection time points, and the organs of 
interest, including tumor tissues, were removed. The organ weights were determined, and 
the radioactivity in the organs was measured with a well-type γ-counter. Several tumor 
model mice were sacrificed 3 hr after the probe injection by transcardial perfusion of 
saline (20 ml) under anesthesia. The weight and radioactivity of the removed organs, 
including tumor tissues, were measured as mentioned above. 
The tumors were removed for metabolite analysis 3 hr after intravenous injection of 
a saline solution including [18F]FTAP1 (185 MBq, 0.1% Tween 20, v/v) in tumor bearing 
mice and homogenized in 1 ml ice-cold 30 mM Tris-HCl buffer (pH = 8.5) containing 5 
mM magnesium acetate at 4 °C. After addition of 3 ml cold methanol and vortexing, 
tissue samples were centrifuged (10,000 x g, 5 min). The supernatants were filtered, and 
the filtrate was analyzed by RP-HPLC as described above. 
The tumors removed 3 hr after injection of [18F]FTAP1 (81 MBq) were also subjected 
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to ex vivo autoradiography and immunohistochemistry. Ten μm thick sections of the 
tumor were prepared with a cryomicrotome (CM1900, Leica Microsystems) and exposed 
to imaging plates (BAS-SR, Fuji Photo Film) for 2 hr. Autoradiograms of these sections 
were obtained with a BAS5000 scanner (Fuji Photo Film). The adjacent sections were 
subjected to immunohistochemical staining for FABP4 and perilipin, an adipocyte marker, 
with hematoxylin counterstaining performed as described in our previous report [9]. A 
FABP4–specific polyclonal rabbit IgG (ab13979, Abcam) and a perilipin–specific 
monoclonal rabbit IgG (D1D8, Cell Signaling) were used as the primary antibodies. 
Antibodies from the Dako Envision + kit (K4002, Dako) were used as secondary 
antibodies for both primary antibodies. Subclass-matched irrelevant IgG served as a 
negative control.  
Dynamic small-animal PET/computed tomography (CT) scans were performed with 
[18F]FTAP1 in tumor-bearing mice. The body temperature was maintained using a heating 
pad throughout the procedure. [18F]FTAP1 (37 MBq, 0.1% tween 20, v/v) was 
intravenously injected into mice, followed by PET scanning acquired over 172–202 min 
(5 min/frame) under isoflurane anesthesia (2.5% in an air mixture). CT scans were 
performed for anatomic reference (spatial resolution, 50 μm; 60 kV; and 310 μA). PET 
and CT images were reconstructed using three-dimensional ordered-subset expectation 
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maximization and a modified three-dimensional cone-beam Feldkamp algorithm 
resulting in a 0.177- x 0.177- x 0.177-mm voxel size for a 512 x 512 x 512 image volume, 
respectively. Acquired images were processed with PMOD Biomedical Image 
Quantification (PMOD Technologies, Ltd.).  
 
8. Statistical analysis 
The Ki values are expressed as mean ± standard errors of the means (SEM), while the 
other data are expressed as mean ± SD. Statistical analysis was performed with the Mann-





1. In vitro evaluation of nonradioactive compounds and radiosynthesis 
A competitive binding assay using the established FABP4 ligand, 1,8-ANS, revealed 
the affinity of FTAP1 and FTAP3 for FABP4. Analysis of inhibition curves allowed 
determination of Ki values of 68 ± 8.9 and 490 ± 41 nM for FTAP1 and FTAP3, 
respectively. The membrane permeability determined by a PAMPA plate system was 1.5 
± 0.3 x 10-6 and 0.18 ± 0.08 x 10-6 cm/s for FTAP1 and FTAP3, respectively. 
Based on the results of these evaluations, FTAP1 was chosen for further experiments. 
[18F]FTAP1 was successfully synthesized following the scheme shown in Fig. 2. The 
radiochemical yield was 31 ± 17%, and the radiochemical purity was above 98% after 
purification by RP-HPLC.  
  
2. In vitro evaluation of [18F]FTAP1 
The selectivity assay of [18F]FTAP1 binding to FABP4 compared with that to FABP3 
and FABP5 (Fig. 3) using each immobilized protein revealed that [18F]FTAP1 binding to 
FABP4 was 16.3-fold higher than to FABP3 and 9.3-fold higher than to FABP5 (6.7 ± 
3.6% dose/μg protein (FABP4) vs. 0.4 ± 0.7% dose/μg protein (FABP3) and 0.7 ± 0.4% 
dose/μg protein (FABP5), P < 0.05). 
24 
 
Cellular uptake of [18F]FTAP1 into adipocytes and 3T3-L1 preadipocytes was 
evaluated to clarify whether [18F]FTAP1 binds to intracellular FABP4 (Fig. 4). Cell 
differentiation and FABP4 expression in differentiated adipocytes were confirmed by Oil 
red O staining and western blot analysis, respectively, in a similar way to that described 
in our previous report [9]. [18F]FTAP1 showed significantly higher radioactivity in 
adipocytes than 3T3-L1 preadipocytes. Furthermore, the radioactivity accumulation in 
adipocytes was significantly and dose-dependently inhibited by treatment with the 
FABP4-specific inhibitor BMS309403, which at 10 μM inhibited almost all (ca. 95%) of 
the total probe uptake. 
The partition coefficient (a logP value) of [18F]FTAP1 was estimated to be 1.7 ± 0.04. 
Over 95% of radioactivity was observed in an intact form by HPLC analysis after 2 hr 
incubation in mouse plasma at 37 °C, which indicates the high stability of [18F]FTAP1. 
The percentage of [18F]FTAP1 bound to serum proteins was found to be more than 99%. 
 
3. In vivo and ex vivo evaluations of [18F]FTAP1 
Table 1 shows the biodistribution of [18F]FTAP1 in C6 tumor bearing mice. 
[18F]FTAP1 was cleared through excretion via the liver and kidneys while low-level 
radioactivity was observed in the bones, suggesting that [18F]FTAP1 was resistant to 
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defluorination in vivo. [18F]FTAP1 showed moderate radioactivity accumulation in 
tumors, which peaked 180 min after injection (3.86 ± 0.39 % ID/g). The tumor to muscle 
ratio of radioactivity accumulation increased in a time-dependent manner and reached 4.5 
at 180 min after probe injection. Considering the high radioactivity retention in 
circulating blood, the influence of blood radioactivity on the radioactivity remaining in 
the tumors was evaluated by comparing the radioactivity accumulation in tumor tissues 
of mice sacrificed by decapitation and transcardial perfusion. While the lung radioactivity 
was reduced by 90%, there was no difference in tumor accumulations, with the 
radioactivity accumulations in tumors and lungs in mice sacrificed by decapitation being 
3.86 and 5.45 % ID/g, respectively, while those in mice sacrificed by transcardial 
perfusion were 4.14 and 0.51 % ID/g, respectively. 
The radioactive chemical composition in tumors 3 hr after [18F]FTAP1 
administration was analyzed by RP-HPLC of excised tumor homogenates (Fig. 5). In 
tumors (Fig. 5B), no distinct metabolite peaks were observed and the retention time of an 
observed main peak was the same as that for [18F]FTAP1 (Fig. 5A). These results indicate 
that [18F]FTAP1 exists in an intact form in tumors. 
Ex vivo autoradiographic analysis (Fig. 6A) showed a heterogeneous radioactivity 
distribution in tumor sections 3 hr after [18F]FTAP1 injection, and the accumulation 
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profile essentially corresponded to FABP4-positive areas (Fig. 6A and B, black arrow). 
The expression of perilipin, an adipocyte marker, was also confirmed in FABP4-positive 
areas (Fig. 6C).  
Finally, PET/CT imaging of tumor-bearing mice was performed 3 hr after 
[18F]FTAP1 injection. As shown in Fig. 7, the tumor in the right hind legs was visualized, 




In the present study we developed [18F]FTAP1 for in vivo PET imaging of FABP4, 
which is closely related to CAA functions [5], tumor progression [5], and atherosclerotic 
plaque instability [13]. This probe is based on our previous radioiodinated probe, 
[123/125I]TAP1 [9]. [18F]FTAP1 showed high affinity and selectivity for FABP4, adequate 
cellular membrane permeability, and high uptake into differentiated adipocytes 
expressing FABP4 that could be perfectly blocked by a selective FABP4 inhibitor. 
[18F]FTAP1 time-dependently accumulated in an intact form in C6 implanted tumors, 
which enabled in vivo tumor imaging with a PET/CT scanner designed for use with small 
animals. Furthermore, the regional radioactivity distribution corresponding to the FABP4 
expression profile in tumor sections was confirmed. Together, these results indicate that 
[18F]FTAP1 is a promising imaging probe that targets FABP4.  
We recently developed and evaluated a novel radioiodinated probe, [123/125I]TAP1, as 
a FABP4 imaging probe [9]. The design of [125I]TAP1 was based on the structures of 
several FABP4 inhibitors, and in vitro results showed superior affinity and selectivity for 
FABP4. However, this probe was highly lipophilic, which led to significant nonspecific 
accumulation in vitro and in vivo, and caused difficulties for in vivo imaging. As such, 
this high lipophilicity was considered to be a critical drawback of [125I]TAP1. In this study, 
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we aimed to reduce the lipophilicity of the FABP4-specific probe for optimization of in 
vivo imaging while maintaining the superior characteristics of the original probe. To 
design a probe that has reasonable lipophilicity and membrane permeability so that 
delivery to intracellular target molecules (e.g. FABP4) can be achieved after 
derivatization, we adopted two strategies: 1) substitution of radiofluorine for radioiodine 
as the labeling radionuclide, and 2) introduction of short oxyethylene linkers between the 
radionuclide and the core probe structure. The introduction of a longer oxyethylene linker 
(FTAP3) excessively diminished membrane permeability and also reduced binding 
affinity to FABP4, probably because of the additional steric hindrance exerted on the 
interaction of FTAP3 with the FABP4 protein. On the other hand, use of a shorter linker 
(single oxyethylene linker) in [18F]FTAP1 successfully provided reasonable lipophilicity 
(the logP values of [18F]FTAP1 and [125I]TAP1 were 1.7 ± 0.04 and 2.7 ± 0.1, 
respectively) and adequate membrane permeability for intracellular targeting [14], while 
retaining a high binding affinity for FABP4. Our results are supported by the previous 
report that investigated the correlation between cell permeability and biophysical 
properties of the compound, including logP values and molecular weight [15]. 
Furthermore, almost all [18F]FTAP1 accumulation in adipocytes was inhibited by 
treatment with the FABP4 inhibitor 10 μM BMS309403, indicating a successful reduction 
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in nonspecific accumulation, compared with radioiodinated TAP1 that showed ~50% 
nonspecific accumulation in the same experimental setting [9]. Thus, as expected, 
[18F]FTAP1 was successfully derived and had a low nonspecific accumulation while 
maintaining FABP4 binding capacity. 
The biodistribution study in tumor bearing mice also revealed a superior property of 
[18F]FTAP1 as compared to [125I]TAP1. Namely, tumor accumulations were 3.9 % dose/g 
and 2.3 % dose/g for [18F]FTAP1 and [125I]TAP1, respectively, while the tumor to muscle 
ratios were 4.5 and 3.6 for [18F]FTAP1 and [125I]TAP1, respectively. The background 
signal might be increased if a blood fraction exists in tumor tissues because circulating 
blood showed somewhat high radioactivity levels. However, the finding that tumors taken 
from mice sacrificed by transcardial perfusion showed comparable radioactivity levels to 
those taken from mice sacrificed by decapitation clearly indicates that the influence of 
residual blood radioactivity on tumor accumulation was low. For future applications, high 
radioactivity remaining in circulating blood could present an obstacle to accurate imaging. 
Since the remaining radioactivity might be due to the high protein binding of [18F]FTAP1, 
a detailed analysis of the interaction between the probe and serum proteins such as 
albumin and acidic glycoprotein would provide information on how this possible 
background effect could be reduced. In any case, PET/CT imaging using [18F]FTAP1 was 
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successful in visualizing C6 cells implanted tumors in living mice, which is consistent 
with the biodistribution study described above. A ring-shaped radioactivity accumulation 
profile observed in the tumor region in PET images might reflect adipocytes that surround 
the tumor and express FABP4, as was indicated in the immunohistochemical results.  
Recently, the role of CAA in tumor progression has been gathering attention. Nieman 
et al. [5] reported that CAAs metabolically interact with SKOV3ip1 cells and promote 
fatty acid metabolism in these cells that is required for proliferation. They also revealed 
that this interaction could be inhibited by a FABP4 inhibitor, and that the expression of 
FABP4 in tumor cells in the boundary areas between tumor cells and CAAs is enhanced. 
Thus, FABP4 could be a key participant in the metabolic interaction between these cells. 
Different tumor cells have been reported to express varying levels of FABP4, while some 
lack this protein [16-18]. Since FABP4 is not expressed in C6 cells in vitro [9] but 
expressed in human glioblastoma lesion in vivo [16], we used C6 cell line as a model 
system leading to increased FABP4 expression in CAAs surrounding C6 tumors to 
evaluate FABP4 targeting probes in vivo. In this study, FABP4 is only expressed in CAAs 
surrounding tumors and [18F]FTAP1 detects them. FABP4 expressed in tumor stromal 
cells is reported to be related to glioma malignancy [16], suggesting that FABP4 imaging 
with [18F]FTAP1 could be useful for evaluating the potential for glioma malignancy. On 
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the other hand, in other tumors, including bladder cancers, FABP4 is reported to be 
expressed in tumor cells and is related to the disease pathology [17, 18]. FABP4 expressed 
in macrophages is also reported to correlate with instability of atherosclerotic plaques 
[13]. Thus, FABP4 imaging could be useful not only for evaluating the detailed functions 
of FABP4 in multiple settings and for the development of therapeutic agents that target 
FABP4, but also for assessing the pathophysiological grades of related diseases.  
 
In conclusion, we developed a novel radiofluorinated probe, [18F]FTAP1, for in vivo 
PET imaging of FABP4 that is closely related to various pathologies in cancers. 
[18F]FTAP1 demonstrated superior in vitro and in vivo characteristics with low non-
specific binding and succeeded in PET imaging of xenografted tumors. These findings 
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Table 1. Radioactivity biodistribution after intravenous administration of [18F]FTAP1 in C6 bearing mice. 
 Time after administration (min) 
 5 30 60 120 180 
Blood 22.27 ± 1.54 15.29 ± 1.92 12.44 ± 1.43 10.12 ± 0.44 10.38 ± 0.56 
Heart 4.56 ± 0.48 4.55 ± 0.47 3.64 ± 0.56 3.03 ± 0.20 2.88 ± 0.50 
Lung 12.74 ± 1.58 10.56 ± 1.52 6.11 ± 1.13 5.45 ± 1.03 5.71 ± 0.77 
Liver 36.32 ± 1.72 31.89 ± 2.65 25.59 ± 4.65 20.50 ± 2.28 17.63 ± 1.08 
Kidney 31.94 ± 6.70 24.42 ± 2.81 20.84 ± 2.99 17.14 ± 2.16 15.19 ± 2.12 
Intestine 17.65 ± 13.11 6.57 ± 0.80 9.96 ± 1.14 13.39 ± 0.37 19.24 ± 3.49 
Stomach
a
 0.54 ± 0.10 0.63 ± 0.10 0.72 ± 0.20 0.97 ± 0.15 0.73 ± 0.32 
Spleen 2.93 ± 0.15 1.96 ± 0.20 1.87 ± 0.08 1.33 ± 0.11 1.55 ± 0.29 
Pancreas 2.66 ± 0.30 2.13 ± 0.08 1.70± 0.30 1.36± 0.18 1.26 ± 0.10 
Muscle 0.78 ± 0.16 0.96 ± 0.15 1.03 ± 0.21 0.98 ± 0.02 0.88 ± 0.13 
Bone 1.45 ± 0.23 1.44 ± 0.14 1.49 ± 0.32 1.28 ± 0.10 1.95 ± 0.58 
Brain 0.36 ± 0.06 0.26 ± 0.04 0.25 ± 0.04 0.20 ± 0.02 0.24 ± 0.01 
Tumor 1.13 ± 0.22 2.48 ± 0.54 2.96 ± 0.16 3.74 ± 0.31 3.86 ± 0.39 
Tumor/Muscle 1.45 ± 0.15 2.57 ± 0.30 2.95± 0.57 3.83 ± 0.28 4.49 ± 0.90 
Tumor/Blood 0.05 ± 0.01 0.16 ± 0.02 0.24± 0.02 0.36 ± 0.04 0.37 ± 0.05 
Data are presented as % injected dose per gram. Each value represents the mean ± s.d. for 3 animals at each 





Synthesis of nonradioactive FTAP1 (3), nonradioactive FTAP3 (6), and FTAP1 precursor 
(10).  
 
Fig. 2  
Radiosynthesis of [18F]FTAP1. 
 
Fig. 3 
Binding of [18F]FTAP1 to the FABP3, 4, and 5 analogues. *P < 0.05 vs. FABP4 group. 
 
Fig. 4.  
Uptake of [18F]FTAP1 into adipocytes and 3T3-L1 cells, and inhibition by BMS309403. 
#P < 0.05 vs. 3T3-L1 group, †P < 0.05 vs. 1 μM group, §P < 0.05 vs. 10 μM group. 
 
Fig. 5.  
Analysis of [18F]FTAP1 in saline (A) and of tumor homogenates at 180 min after 
intravenous injection of [18F]FTAP1 (B).      
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 Fig. 6. 
Regional distribution determined by autoradiography of radioactivity 180 min after the 
injection of [18F]FTAP1 (A). FABP4 and perilipin immunohistochemical staining of 
sections adjacent to A (B, C). Bar = 1 mm (B, C). 
 
Fig. 7. 
PET/CT imaging 180 min after [18F]FTAP1 injection into C6 bearing mice. 
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